CD8-deficient SJL mice display enhanced susceptibility to Theiler’s virus infection and increased demyelinating pathology

Wendy Smith Begolka, Lia M Haynes, Julie K Olson, Josette Padilla, Katherine L Neville, Mauro Dal Canto, Joann Palma, Byung S Kim, and Stephen D Miller

Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Medical School, Chicago, Illinois, USA

Theiler’s murine encephalomyelitis virus (TMEV) infection of the central nervous system (CNS) induces a chronic, progressive demyelinating disease in susceptible mouse strains characterized by inflammatory mononuclear infiltrates and spastic hind limb paralysis. Our lab has previously demonstrated a critical role for TMEV- and myelin-specific CD4 T cells in initiating and perpetuating this pathology. It has however, also been shown that the MHC class I loci are associated with susceptibility/resistance to TMEV infection and persistence. For this reason, we investigated the contribution of CD8 T cells to the TMEV-induced demyelinating pathology in the highly susceptible SJL/J mouse strain. Here we show that β2M-deficient SJL mice have similar disease incidence rates to wild-type controls, however β2M-deficient mice demonstrated earlier onset of clinical disease, elevated in vitro responses to TMEV and myelin proteolipid (PLP) epitopes, and significantly higher levels of CNS demyelination and macrophage infiltration at 50 days post-infection. β2M-deficient mice also displayed a significant elevation in persisting viral titers, as well as an increase in macrophage-derived pro-inflammatory cytokine mRNA expression in the spinal cord at this same time point. Taken together, these results indicate that CD8 T cells are not required for clinical or histologic disease initiation or progression in TMEV-infected SJL mice. Rather, these data stress the critical role of CD4 T cells in this capacity and further emphasize the potential for CD8 T cells to contribute to protection from TMEV-induced demyelination.

Keywords: β2-microglobulin; CD8; Theiler’s virus; demyelination; multiple sclerosis

Introduction

Although the etiology of multiple sclerosis (MS), an immune-mediated demyelinating disease of the central nervous system (CNS) in humans, remains largely unknown, several lines of evidence suggest the potential for a virus as the initial causative agent (Kurtzke, 1993; Waksman, 1995). Theiler’s murine encephalomyelitis virus (TMEV) is a member of the Picornaviridae family that induces a chronic progressive demyelinating pathology that closely resembles MS in susceptible strains of mice following
intracerebral inoculation. TMEV-induced demyelinating disease (TMEV-IDD) is characterized clinically by an abnormal waddling gait resulting from an ascending hind limb spastic paralysis, and histologically by the presence of perivascular inflammatory mononuclear infiltrates within the CNS that result in primary demyelination (Lipton and Dal Canto, 1979; Miller and Karpus, 1994).

It is believed that the mechanisms involved in the development of demyelination involve both direct and bystander immune-mediated processes as evidenced by the presence of inflammatory CD4⁺ and CD8⁺ T cells and macrophages within the target organ (Lipton et al., 1984; Pope et al., 1996), and to a lesser extent, direct viral damage of oligodendrocytes and microglia due to persistent viral infection (Rodriguez et al., 1983; Graves et al., 1986; Rodriguez et al., 1988; Ohara et al., 1990). However, the exact nature of these immune effector responses and their contribution to disease pathogenesis is still a matter of some controversy. There is considerable evidence from our own lab, as well as others, that indicates a critical role for CD4⁺ Th1 cells in mediating both the initial and chronic pathogenesis of TMEV-IDD in the susceptible SJL/J strain, as demonstrated by antibody depletion studies (Rodriguez et al., 1986a; Friedmann et al., 1987; Welsh et al., 1987), the correlation of delayed-type hypersensitivity (DTH) responses with the severity of disease (Miller et al., 1997), and the increasing amounts of CD4⁺ Th1-derived pro-inflammatory cytokines expressed in the CNS throughout disease progression (Begolka et al., 1998). Despite these significant findings, there also exist numerous lines of often contradictory evidence from similar studies conducted in resistant C57BL/6 mice with gene deletions to additionally support the role of CD8⁺ T cells, not only in viral clearance and protection but also in promoting the demyelinating process (Rodriguez et al., 1986a; Rodriguez and Sriram, 1988; Fiette et al., 1993; Pullen et al., 1993; Njenga et al., 1996; Murray et al., 1998).

Therefore, in this study we sought to definitively establish the effector role of CD8⁺ T cells in the highly susceptible SJL/J mouse, by utilizing mice which are deficient in the expression of β2-microglobulin (β2M), which fail to positively select any CD8⁺ T cells (Koller et al., 1990; Zijlstra et al., 1990). Our results clearly indicate, in correlation with our previous data in this system, that CD8⁺ T cells fail to provide a significant and demonstrable effector contribution to either the initiation or progression of TMEV-IDD clinical pathology or demyelination. In addition, our data also convincingly demonstrates that the absence of CD8⁺ T cells leads to an accelerated and more severe disease phenotype, as measured clinically, histologically, and by several in vitro parameters, leading to the conclusion that the role of CD8⁺ T cells is primarily for protection and/or regulation in this system. These data are consistent with our ongoing model for the SJL/J mouse wherein persistent CNS infection with TMEV leads to the continual activation and clonal expansion of TMEV-specific, and eventually neuroantigen-specific, CD4⁺ Th1 effector cells capable of secreting proinflammatory cytokines and chemokines. These proinflammatory molecules in turn lead to the recruitment and eventual accumulation of activated macrophages/microglia within the CNS resulting in demyelination via a nonspecific bystander response.

Results

Accelerated onset and increased clinical severity of TMEV-IDD in β2M-deficient mice

Wild-type SJL and β2M-deficient mice were monitored for the development of clinical signs of demyelination following infection with TMEV (Figure 1). Although the incidence rate for developing TMEV-IDD was not statistically distinct between the two groups (93.1% vs 75.8%), β2M-deficient mice developed a heightenened disease phenotype as measured by several parameters. β2M-deficient mice had an accelerated disease onset when compared to control mice (MDO = 29.89 vs 35.08; P < .038), and a rapidly progressing chronic disease that was dramatically increased in severity over controls from day 32 postinfection (p.i.) throughout the measured clinical course.

The increased disease severity in the β2M-deficient mice was also evident from gross CNS histology at day 50 p.i. (Figure 2), showing large numbers of perivascular and parenchymal inflammatory infiltrates, which appear to be comprised primarily of...
myelin debris-containing macrophages, as well as extensive white matter demyelination, compared to the milder perivascular CNS damage in wild-type controls. To address if there were qualitative and/or quantitative changes in the nature of the inflammatory infiltrate between the two groups, we also performed immunohistochemistry for CD4, CD8, and F4/80 infiltrates. The increased CNS infiltrates in the β2M-deficient mice were largely the result of accumulation of F4/80+ macrophages/microglia, rather than CD4+ effector cells which were fairly equivalent between wild-type and β2M-deficient mice (Figure 3). As expected, staining for CD8+ T cells was detected in the wild-type infected CNS, albeit at low levels, yet completely absent in β2M-deficient mice, confirming their phenotype. Isotype-matched controls for each antibody as well as staining of CNS tissue from naïve mice revealed no positive cells for any of the three tested markers (data not shown).

Increased viral persistence in the CNS of TMEV-infected β2M-deficient mice While the clinical and histological disease was exacerbated in the β2M-deficient mice, it was also of interest to determine if the severe disease pathology could be attributed to alterations in viral clearance within the CNS due to the lack of cytolytic CD8+ T cells. Viral plaque assays of brain and spinal cord tissue from TMEV-infected β2M-deficient mice at day 50 p.i. revealed a 2–2.5-fold increase in viral titer from both the brain and spinal cord as compared to the wild-type control mice (Figure 4A). Overall, higher levels of virus were isolated from the spinal cord in both groups correlating with the previous observation that TMEV persists to a higher level in this CNS tissue at later time points in disease (Lipton et al., 1984). As expected, homogenized kidney samples from both TMEV-infected groups failed to yield any detectable plaques (data not shown). Semiquantitative RT-PCR from spinal cord samples at this same time point also demonstrated an increase in mRNA levels for the TMEV capsid proteins VP1 and VP3 as seen in the plaque assays (Figure 4B). This data illustrates the critical role of the CD8+ T cell in the highly susceptible SJL mouse in regulating levels of infectious virus, and not in contributing to the TMEV-IDD demyelinating pathology.

T cell responses to both TMEV and myelin epitopes are increased in β2M-deficient mice The data to this point indicate that the clinical presentation of TMEV-IDD differs dramatically in the presence or absence of CD8+ T cells in the SJL host, and that in β2M-deficient mice the exacerbated disease severity may be attributed to the pronounced inflammatory infiltrate and increased viral titer. We next sought to determine if the pattern of peripheral immune reactivity to TMEV and myelin proteins, as measured by both in vivo and in vitro assays was altered between the β2M-deficient and control mice, and thereby provide additional evidence of a contributing mechanism for the observed accelerated disease. Delayed-type hypersensitivity (DTH) analysis of TMEV-infected β2M-deficient at day 50 p.i. demonstrated no significant difference in the level of in vivo reactivity to either UV-inactivated TMEV, the immunodominant VP2 70-86 capsid protein peptide, or the immunodominant myelin epitope PLP139-151 when compared to the wild-type infected controls (Figure 5). This does...
Severe TMEV-IDD pathology in CD8-deficient SJL mice

Figure 3  Immunohistochemical staining for CD4+ and CD8+ T cells, and F4/80+ macrophages/microglia in the spinal cords of wild-type and β2M-deficient SJL mice with TMEV-IDD. Spinal cord sections from mice from day 50 p.i. were stained for expression of CD4, CD8, and F4/80 as described in Materials and Methods. Shown is a representative section from each group of mice for each cell surface marker. In the top panels F4/80 staining is shown in red; in the middle panels, CD4 staining is shown in green with a blue DAPI counterstain; and, in the bottom panels, CD8 staining is shown in blue with red propidium iodide counterstain. Magnification is 100 x. Isotype-matched control antibody did not stain spinal cords from affected mice, nor was any positive staining revealed in the spinal cords of naïve mice (data not shown).
Severe TMEV-IDD pathology in CD8-deficient SJL mice
WS Begolka et al

Figure 4  Increased viral titers and mRNA for viral proteins are found in the brain and spinal cord of TMEV-infected $\beta$2M-deficient SJL mice. In panel A, three mice at day 60 p.i. from each group were sacrificed, and brain, spinal cord, and kidney (not shown) were isolated, pooled, and processed for a viral plaque assay as described in Materials and Methods. Viral plaques in a BHK monolayer were counted over a series of four dilutions of tissue lysate, with the data shown as the mean PFU (plaque forming unit) per mg of brain and spinal cord starting tissue. Control kidney lysate did not yield any viral plaques. These results are representative of two separate experiments. In panel B, spinal cord-derived RNA from mice at day 60 p.i. was used as a template for semi-quantitative RT-PCR for the TMEV viral capsid proteins VP1 (495bp) and VP3 (445bp).

indicate, however, that $\beta$2M-deficient mice are fully competent in developing and sustaining a CD4$^+$ Th1-mediated response.

Although this observation is interesting, it is also possible that we may have missed an accelerated activation and expansion of PLP139-151-specific T cells at the day-50 time point, given that the majority of $\beta$2M-deficient mice have already progressed to a severe clinical disease, and may now be displaying enhanced reactivity to additional myelin epitopes not tested. We therefore performed DTH at an earlier time point in disease (day 35 p.i.), and despite yielding similar results for TMEV and VP2 70-86, the $\beta$2M-deficient mice now displayed a trend (bordering on significance) toward increased responses to PLP139-151 compared to controls, indicative of accelerated epitope spreading (data not shown).

This trend toward increased neuroantigen reactivity was also observed in the in vitro splenic proliferative responses to both viral and myelin epitopes. $\beta$2M-deficient mice demonstrated comparable to slightly higher responses, as measured by stimulation indexes, to intact TMEV and VP2 70-86 (Figure 6A), yet dramatically increased reactivity to PLP139-151 (SI = 10.1 vs 3.2) (Figure 6B). Responses to the irrelevant antigen OVA 323-339 were not detected in any experimental group. Given that we have previously demonstrated the ability to detect only low levels of proliferation to this immunodominant epitope at this time point from wild-type animals (Miller et al., 1997), collectively these data additionally support the immunological phenomenon of epitope spreading as a contributing factor in the accelerated disease phenotype observed in the $\beta$2M-deficient mice.

Increased levels of macrophage-derived pro-inflammatory mediators in the CNS of $\beta$2M-deficient mice  With evidence of increased cellular infiltrate, viral titer and cellular responses, we were also
Severe TMEV-IDD pathology in CD8-deficient SJL mice

Discussion

A large body of research has attempted to ascertain whether CD4+ or CD8+ T cells are involved in the initiation, progression and/or regulation of TMEV-IDD. The evidence for CD4+ T cells as mediators of TMEV pathology in susceptible SJL mice is significant in that: 1) monoclonal antibodies against CD4, MHC Class II, or IL-12 either prevented or diminished clinical signs (Friedmann et al, 1987; Welsh et al, 1987; Inoue et al, 1998); 2) flow cytometric and histological data from infected SJL/J mice revealed an increased level of CD4+ T cells and their pro-inflammatory cytokines during clinical disease progression, and transfer of a CD4+ VP2-specific T cell line leads to increased incidence and accelerated onset of disease (Gerety et al, 1994; Pope et al, 1996; Begolka et al, 1998); 3) the development of virus and myelin antigen-specific DTH corresponds with onset and chronicity of demyelination (Clatch et al, 1986; Miller et al, 1997); 4) epitopes of TMEV that elicit a Th1 response and DTH can accelerate the pathogenesis of TMEV upon active immunization (Yauch et al, 1998); and 5) tolerance via ECDI-coupled cells with TMEV, known to reduce IL-2 and IFN-γ from Th1 cells, reduces the severity of disease (Peterson et al, 1993; Karpus et al, 1995).

Although these data seem to rigorously support the role of CD4+ Th1 cells in both initiation and progression of TMEV-IDD, there are also a number of published reports suggesting the same is true for CD8+ T cells (Rodriguez et al, 1986a; Rodriguez and Sriram, 1988; Matloubian et al, 1994; Njenga et al, 1996; Murray et al, 1998). However, as the majority of these studies were conducted using mice on a resistant genetic background (C57BL/6 and 129/J), in this study we sought to determine the outcome of the TMEV-IDD disease phenotype in the absence of CD8+ T cells in the highly susceptible SJL/J mice that were deficient in the expression of β2M. Previous reports examining the effects of this mutation or the MHC class I knockout counterpart have provided evidence that the absence of CD8+ T cells on the resistant background leads to the establishment of chronic demyelination with or without clinical signs, extensive CNS infiltrate, and high viral titers, leading one to conclude that the primary role of these cells is in protection and regulation of disease (Fiette et al, 1993; Pullen et al, 1993; Rodriguez et al, 1993; Rivera-Quinones et al, 1998; Lavi et al, 1999). The current results support this central role for CD8+ T cells, with
Figure 7  Semiquantitative RT-PCR analysis of cytokine mRNA levels from the spinal cords of TMEV-infected β2M-deficient and wild-type control SJL mice. At 50 days p.i., three mice per group were sacrificed by perfusion and spinal cord RNA was isolated. This total RNA served as the template for RT-PCR as detailed in Materials and Methods. Shown in panel A are the gel images of the amplified products for the control transcript HPRT, the macrophage/microglia cell surface marker F4/80, and the macrophage-derived proinflammatory mediators, TNF-α, IL-12, IL-10, and iNOS. Shown in panel B are the amplified products of the effector T cell marker CD4 and the T cell-derived cytokines IFN-γ, IL-4, and TNF-β (lymphotoxin). Shown in panel C are the densitometry values for the amplified cytokine products in panels A/B following normalization to the housekeeping gene, HPRT. The data are expressed as a percentage of normalized HPRT expression. Results are representative of two separate experiments.
the secondary conclusion that CD4\(^+\) effector T cells are sufficient to mediate disease pathogenesis. First, \(\beta 2M\)-deficient mice are highly susceptible to TMEV-IDD, as there was no difference in the incidence rate when comparing them to control mice; however, their progression of disease was remarkable when observing several severity parameters. \(\beta 2M\)-deficient mice displayed an accelerated onset of disease, as well as a more severe clinical progression as measured by mean clinical score over the duration of the time course observed. In addition, in one experiment where the mice were allowed to progress to beyond 55 days p.i., 5 out of 11 \(\beta 2M\)-deficient mice progressed to a clinical score of 4, with several mice eventually succumbing to the disease by day 60, an observation rarely seen with the wild-type SJL/J mouse (data not shown). Second, the severe clinical disease in the \(\beta 2M\)-deficient mice also correlated with the presence of large numbers of inflammatory infiltrates comprised mainly of activated macrophages/microglia in conjunction with extensive white matter demyelination as compared to the control mice. Expression of cytokine mRNA from the CNS of infected mice additionally confirms the increase in activated macrophage/microglia infiltrate as well as their secreted pro-inflammatory mediators known to promote the CD4\(^+\) Th1 environment. Third, \(\beta 2M\)-deficient mice were effectively able to mount a specific immune response to both virus and myelin epitopes that was at a minimum equivalent to, yet often exceeded, that of wild-type controls. Last, \(\beta 2M\)-deficient mice were significantly hampered in their ability to control viral persistence in both the brain and spinal cord.

Impressively, the current data extend the prior work done with resistant animals to the susceptible SJL/J mouse and confirm the phenotype previously observed. This correlation between outcomes regardless of the genetic background lends strong support to the distinct roles of CD4\(^+\) and CD8\(^+\) T cells in the TMEV model. Although data indicating the pivotal role of CD4\(^+\) T cells in the pathogenesis of TMEV-IDD have been previously reported, an equally compelling body of work also demonstrates the critical role CD8\(^+\) T cells play in the control of disease susceptibility. It has been clearly shown that: 1) susceptibility/resistance to TMEV maps to Class I H-2D (Clatch et al., 1985; Rodriguez and David, 1985; Rodriguez et al., 1986b; Kappel et al., 1991); 2) monoclonal antibody depletion of CD8\(^+\) T cells leads to earlier onset and increased disease severity (Larsson-Sciard et al., 1997); 3) virus-specific CTLs are found at a higher frequency in the CNS of resistant mice than susceptible mice, and in vivo IL-2 therapy can effectively boost CTL responses in susceptible strains and diminish viral persistence (Lindsay et al., 1991; Pena Rossi et al., 1991; Lin et al., 1995; Dethlefs et al., 1997); 4) perforin KO mice on the normally resistant C57BL/6 background are able to be persistently infected with TMEV (Pena-Rossi et al., 1998); and 5) in the BALB/c system, transfer of a CD8\(^+\) population from the spleen of TMEV-infected donors protects recipients from disease induction (Nicholson et al., 1996; Haynes et al., 2000). Taken as a whole, our data in the susceptible SJL/J mouse supplement and are consistent with these previously documented observations and further support a critical role for CD8\(^+\) T cells in regulating disease susceptibility and severity.

Our results are, however, in direct contrast with data suggesting CD8\(^+\) T cells contribute to the disease pathology of TMEV-IDD (Rivera-Quinones et al., 1998; Rodriguez and Sriram, 1988). There are several possible explanations for these observed differences. With regard to the absence of CD4\(^+\) T cells leading to an exacerbated disease, the ability to provide cognate B cell to help production of antibody to control the peripheral and CNS viremia is critically impaired (Borrow et al., 1993). This is supported by the fact that the anti-TMEV humoral response in susceptible animals is unable to completely clear the virus but is capable of dramatically limiting the spread early in the infection (Lipton and Gonzalez-Scarano, 1978). To that end, CD4-deficient animals die of an overwhelming virally mediated encephalitis within 25 days p.i. (Rodriguez and Sriram, 1988). The depletion of CD4\(^+\) T cells in the chronic stages of TMEV-IDD has not been directly addressed in the literature to this point, however, given the compelling evidence for a pathologic role of myelin-specific autoimmunity in chronic disease progression (Miller et al., 1997), it is strongly believed that infiltrating CD4\(^+\) T cells contribute more significantly to disease progression than its regulation. Our lab has recently addressed this hypothesis through the use of tolerance to a panel of myelin autoepitopes at later time during chronic disease with the observed outcome of diminished clinical score and decreased demyelinating pathology (manuscript submitted). In addition, as it has been demonstrated that susceptible mice are capable of mounting virus-specific CTL responses (Lindsay et al., 1991), it is interesting to note that CD4\(^+\) T cells have been reported to be required to perpetuate long-term CTL reactivity when infections become persistent, as in the case of LCMV (Matloubian et al., 1994).

The observation that the absence of CD8\(^+\) T cells leads to a less severe disease is more difficult to reconcile with our data (Rivera-Quinones et al., 1998). It is possible that differences related to the strain of virus used (DA vs BeAn) may be a contributing factor, as it has not been completely determined what type of CD8\(^+\) responses are elicited during active infection with each strain of virus. It is well documented in both human and mouse that naive CD8\(^+\) T cells are capable of differentiating into Tc1 or Tc2 populations, analogous to Th1 and Th2 cells, depending on the cytokine environment present during initial stimulation (Groff et al., 1994; Sad et al., 1995; Sad
and Mosmann, 1995; Seder and Le Gros, 1995; Carter and Dutton, 1996). Tc1 development is promoted by IL-18, IL-12, and IFN-γ leading to more of a cytolytic response, whereas Tc2 development is promoted by IL-4 leading to a predominant regulatory response (Li et al., 1997). It is possible, then, that in the resistant C57BL/6 strain, where virus is cleared rapidly, that the predominant response is Tc1 in nature. This idea is supported by data indicating that C57BL/6-perforin KO mice are able to be persistently infected with TMEV (Pena-Rossi et al., 1998), and that the absence of CD8⁺ T cells leads to viral titers that are dramatically increased (Figure 4) (Fiette et al., 1993; Pullen et al., 1993; Rodriguez et al., 1993; Rivera-Quinones et al., 1998; Lavi et al., 1999). This would be in contrast to the susceptible SJL/J strain where the predominant response may be Tc2 in nature, and/or minimally a weak Tc1, and the initial viremia is controlled, but not cleared. These mice, although capable of mounting a cytolytic response during active infection, must be dependent on additional mechanisms to support viral clearance, with the most likely candidate being antibody-dependent responses. This is supported by our observation that the majority of β2M-deficient mice, while displaying an accelerated disease onset and severity of TMEV-IDD, do not succumb to the pathology until after 60 days p.i. Their rapid progression of disease is then most likely a combination of increased viral titer leading to enhanced immune infiltration and demyelination rather than a virally mediated encephalitis, indicative of a significant regulatory response that is now absent.

Collectively, the current data lend additional support to our model of TMEV-IDD in the susceptible SJL/J mouse wherein persistent CNS infection with TMEV leads to the continual activation and clonal expansion of TMEV-specific, and eventually neuroantigen-specific, CD4⁺ Th1 effector cells capable of secreting pro-inflammatory cytokines and chemokines. These pro-inflammatory molecules continue to promote an environment favoring Th1 activation, and in turn lead to the additional recruitment and eventual accumulation of activated macrophages/microglia within the CNS resulting in demyelination via a nonspecific bystander response. The role of CD8⁺ T cells in this model appears to be a combination of both Tc1 cytolytic and Tc2 regulatory responses, but overall they do not appear to contribute significantly to either the demyelinating pathology or the onset of neurological deficit.

Materials and methods

Mice Female SJL/J mice, 6–7 weeks old, were purchased from Harlan Laboratories (Indianapolis, IN). β2M-deficient SJL/J mice were purchased from the Jackson Labs (Bar Harbor, ME). All mice were housed in the Northwestern animal care facility and maintained on standard laboratory chow and water ad libitum. Severely paralyzed mice were afforded easier access to food and water.

Peptides PLP139-151(HSLGKWLGHPDKF), OVA 323-339 (ISQAVHAAHAEINAGR), and VP2 70-86 (WTTSQEAFSHIRPLP) were purchased from the Peptides International (Louisville, KY). Amino acid composition was verified by laser desorption mass spectroscopy and purity (>98%) was assessed by HPLC.

Induction and clinical evaluation of TMEV-IDD Mice were anesthetized with methoxyflurane (Mallinckrodt Veterinary, Mundelein, IL) and inoculated in the right cerebral hemisphere with (2.9 × 10⁶) plaque-forming units of TMEV, strain BeAn 8386, in 30 μl DMEM. Mice were examined in a single-blinded fashion 2–3 times per week for the development of chronic gait abnormalities and spastic paralysis indicative of demyelination, and assigned a clinical score of 0 to 6 as follows: 0 = asymptomatic, 1 = mild waddling gait, 2 = severe waddling gait, intact righting reflex, 3 = severe waddling gait, spastic hind limb paralysis, impaired righting reflex, 4 = severe waddling gait, spastic hind limb paralysis, impaired righting reflex, mild dehydration, and/or malnutrition, 5 = total hind limb paralysis, severe dehydration, and/or malnutrition, 6 = death. The data are plotted as the mean clinical score for animals from three pooled experiments.

In vitro T cell proliferation assays T cell proliferative responses were assessed by incorporation of [³H]-thymidine. A total of 10⁶ viable splenocytes recovered from TMEV infected mice at day 50 p.i. were cultured in triplicate in 96-well, flat-bottom plates in 0.2 ml HL-1 media (Biowhittaker, Walkersville, MD) supplemented with 5% FBS (Sigma, St. Louis, MO), 2 mM glutamine, 100 μg/ml streptomycin, and 100 U/ml penicillin (Gibco BRL, Gaithersburg, MD). A range of VP2 70-86, PLP139-151, and OVA323-339 peptide antigen concentrations (0.1–100 μM final), and 5 μg of UV-inactivated intact TMEV were tested. Plates were pulsed with 1 μCi [³H]-thymidine after 72 h of culture and harvested for scintillation counting on a Packard TopCount plate reader 24 h later. The results are expressed as mean CPM of antigen containing cultures.

Delayed-type hypersensitivity (DTH) DTH responses were quantitated using a standard 24-h ear-swelling assay. Prechallenge ear thickness was determined using a Mitutoyo model 7326 engineer's micrometer (Schlesinger Tools, Brooklyn, NY). DTH responses were elicited by injected 10 μg of peptide (in 10 μl of PBS), or 5 μg of UV-inactivated TMEV into the dorsal surface of the ear using a 100-μl Hamilton syringe fitted with a 30-gauge needle. Twenty-four h after ear challenge, the increase in ear thickness over pre-challenge measurements was determined. Results are expressed in units of 10⁻⁶ in ± SEM. Ear-swelling responses were the result of mononuclear
cell infiltration and showed typical DTH kinetics (i.e., minimal swelling at 4 h, maximal swelling 24–48 h).

**CNS histology**  At day 50 p.i., 2 mice from each group were anesthetized and sacrificed by perfusion through the left ventricle with 10 ml of PBS, followed by 100 ml of chilled 3% glutaraldehyde in PBS, pH 7.3. Spinal cords were dissected from the vertebral canal, sectioned at 1-mm intervals, postfixed in 1% osmic acid for 1 h, and processed for Epon embedding. Ten 1-µm-thick sections from each spinal cord were stained with toluidine blue and examined by light microscopy. Pathologic changes were graded in a blinded manner as follows: −, no disease; +/−, meningeal inflammation; +, focal parenchymal inflammation with demyelination; ++, multiple areas of parenchymal inflammation and demyelination; ++++, extensive inflammation and demyelination with confluent lesions.

**Immunohistochemistry for CD4, CD8, and F4/80**  At day 50 p.i., 2 mice from each group were anesthetized and sacrificed by perfusion through the left ventricle with 30 ml of ice-cold PBS. Spinal cords were removed by dissection, and 2–3-mm spinal blocks were immediately frozen in OCT (Miles Laboratories, Elkhart IN) in liquid nitrogen. The blocks were stored at −80°C in plastic bags to prevent dehydration. Then, 5–6-µm-thick sections from the lumbar region (approximately L2-L3) were cut on a Reichert-Jung Cryocut 1800 cryotome (Leica Instruments, Deerfield, IL), mounted on Superfrost Plus electrostatically charged slides (Fisher Scientific, Hanover Park, IL), air dried, and stored at −80°C.

Slides were stained using Tyramide Signal amplification (TSA) Direct Kit (NEN Life Science Products, Boston, MA) according to the manufacturer’s instructions. Sections from each group were thawed, air-dried, fixed in acetone at room temperature, and rehydrated in 1× PBS. Nonspecific staining was blocked using anti CD16/CD32 (FcII/III-2.4G2, Pharmingen, San Diego, CA), and an avidin/biotin blocking kit (Vector Laboratories, Burlingame, CA) in addition to the blocking reagent provided by the TSA kit. Slides were stained with the following biotin-conjugated antibodies: anti-macrophage (F4/80) (Caltag, Burlingame, CA); anti-CD4 (H129.19), and anti-CD8a (53-6.7) (Pharmingen). Sections were counterstained with DAPI (Sigma) or propidium iodide (Molecular Probes, Eugene, OR), and then coverslipped with Vectashield mounting medium (Vector). Slides were then examined by epifluorescence using a chroma triple-band filter (Chroma Technology Corporation, Brattleboro, VT). Four serial sections from each sample per group were analyzed at 100× and 400× magnification throughout the entire spinal cord section, which included gray and white matter, and dorsal, ventral, and lateral regions.

**Plaque assay for viral titer**  At day 50 p.i., 3–4 mice per group were sacrificed by anesthesia. The brain, spinal cord, and kidney were removed and homogenized in PBS, and diluted in serum-free DMEM to obtain at least three serial dilutions for the assay. BHK-21 cells seeded 2 days prior in 60 × 15-cm tissue culture plates, and grown to confluency, were washed 1× with serum-free DMEM prior to the addition of homogenized tissue dilutions. Infection of the BHK cells is accomplished by incubation of the serial dilutions of homogenate with the cells at room temperature for 1 h with occasional swirling. A sterile 2% trypan blue solution is added in equal volume to 2× DMEM supplemented with 2% FBS, 5 mM L-glutamine, 200 µg/ml penicillin, and 200 µg/ml streptomycin. After the 1-h incubation, the DMEM/agar mixture is added to the plate and the BHK cells are incubated at 34°C for 6 days in a humidified environment. Following the 6-day incubation, the agar layer is removed and the BHK cells are fixed with methanol. The cells are then stained with a crystal violet solution (6 g crystal violet, 100 ml ethanol, and 400 ml H2O), and the plaques are visualized on each plate. The number of plaques counted on each plate are multiplied by the homogenate dilution and the amount of homogenate added to the plate to determine the plaque forming units (PFU) per ml. The weight of the original starting tissue (mg) per ml of homogenate is then used to calculate the PFU/ml.

**Isolation of RNA**  At day 50 following induction of TMEV-IDD, two mice from each group were anesthetized and perfused through the left ventricle with 50 ml of PBS. Spinal cords were removed by flushing the vertebral canal with PBS and then rinsed in PBS. Tissues were forced through a 100-mesh stainless steel screen to give a single cell suspension and pelleted by centrifugation at 1200 RPM for 5 min at 4°C. The pellets were vigorously resuspended in 16 ml of 4 M guanidinium isothiocyanate/50 mM Tris-Cl (pH 7.5)/25 mM EDTA (Gibco BRL); 1% 2-mercaptoethanol. Shearing of DNA was facilitated by forcing the resulting suspension repeatedly through a 23-gauge needle. Total RNA was isolated by high-speed gradient centrifugation (27,000 RPM) of 8 ml lysate through a 3 ml 5.7 M CsCl pad using a SW41 swinging bucket rotor for 20 h at 4°C. The resulting RNA pellet was resuspended to a final concentration of 1 µg/µl with diethylpyrocarbonate (DEPC)-treated water and stored in aliquots at −70°C.

**First strand cDNA synthesis and RT-PCR**  First strand cDNA was generated from 2 µg total RNA using Advantage-RT Kit (Clontech, Palo Alto, CA) using 20 pmole oligo-dt primer as per the manufacturer’s provided protocol in a total volume of 20 µl. Following first strand synthesis, each cDNA sample was brought to a final volume of 100 µl with distilled water. Final PCR conditions included 50 mM KCl; 10 mM Tris-Cl (pH 8.3); 2.5–5.0 mM MgCl2 (empirically determined for each primer pair); 2 mM dNTPs; 100 pmoles of each 5’ and 3’ gene-specific primer; 1 U Taq polymerase (Qiagen, Chatsworth, CA) and 5–10 µl diluted cDNA. Cycling conditions were 94°C, 40 s; 60°C, 20 s; 72°C, 40 s, for a total of 30 cycles;
linked to a final 72°C extension program for 3 min and then to a final 4°C soak program. PCR products were run on an ethidium-bromide-containing 2% agarose gel and illuminated using an ultraviolet light source, then photographed using Polaroid type 667 film. Gel images were then scanned into Adobe Photoshop using an Epson 1200-C scanner and imported as TIFF files into Kodak 1D Digital Science for densitometry. The sum intensity and band area were determined for each amplified product and adjusted to each sample’s housekeeping gene, HPRT. Data are expressed as a percentage of normalized HPRT expression.

Acknowledgement

This work was supported by USPHS NIH Grant NS-23349.

References

Begolka WS, Vanderlugt CL, Rahbe SM, Miller SD (1998). Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 161: 4437–4446.

Borrow P, Welsh CJ, Nash AA (1993). Study of the mechanisms by which CD4+ T cells contribute to protection in Thelier’s murine encephalomyelitis. Immunology 80: 502–506.

Carter L, Dutton RW (1996). Type 1 and type 2: A functional dichotomy for all T cell subsets. Curr Opin Immunol 8: 336–342.

Clatch RJ, Lipton HL, Miller SD (1986). Characterization of Thelier’s murine encephalomyelitis virus (TMEV)-specific delayed-type hypersensitivity responses in TMEV-induced demyelinating disease: Correlation with clinical signs. J Immunol 136: 920–927.

Clatch RJ, Melvold RW, Miller SD, Lipton HL (1985). Thelier’s murine encephalomyelitis virus (TMEV)-induced demyelinating disease in mice is influenced by the H-2D region: Correlation with TMEV-specific delayed-type hypersensitivity. J Immunol 135: 1408–1414.

Croft M, Carter L, Swain SL, Dutton RW (1994). Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J Exp Med 180: 1715–1728.

Dethlefs S, Brahic M, Larsson-Sciard EL (1997). An early, abundant cytotoxic T-lymphocyte response against Thelier's virus is critical for preventing viral persistence. J Virol 71: 8875–8878.

Fiette L, Aubert C, Brahic M, Pena Rossi C (1993). Thelier's virus infection of β2-microglobulin-deficient mice. J Virol 67: 589–592.

Friedmann A, Frankel G, Lorch Y, Steinman R (1987). Monoclonal anti-I-A antibody reverses chronic paralysis and demyelination in Thelier's virus-infected mice: Critical importance of timing of treatment. J Virol 61: 898–903.

Gerety SJ, Rundell MK, Dal Canto MC, Miller SD (1994). Class II-restricted T cell responses in Thelier's murine encephalomyelitis virus (TMEV)-induced demyelinating disease. VI. Potentiation of demyelination with and characterization of an immunopathologic CD4+ T cell line specific for an immunodominant VP2 epitope. J Immunol 152: 919–929.

Graves MC, Bologna L, Siegel L, Londe H (1986). Thelier’s virus in brain cell cultures: Lysis of neurons and oligodendrocytes and persistence in astrocytes and macrophages. J Neurosci Res 15: 491–501.

Haynes LM, Vanderlugt CL, Dal Canto MC, Melvold RW, Miller SD (2000). CD8+ T cells from Thelier’s virus-resistant BALB/cByJ mice downregulate pathogenic virus-specific CD4+ T cells. J Neuroimmunol 106: 43–52.

Inoue A, Koh CS, Yamazaki M, Yahikozawa H, Ichikawa H, Nagita H, Kim BS (1996). Suppressive effect on Thelier's murine encephalomyelitis virus-induced demyelinating disease by the administration of anti-IL-12 antibody. J Immunol 161: 5586–5593.

Kappel CA, Dal Canto MC, Melvold RW, Kim BS (1991). Hierarchy of effects of the MHC and T cell receptor beta-chain genes in susceptibility to Thelier's murine encephalomyelitis virus-induced demyelinating disease. J Immunol 147: 4322–4326.

Karpus WJ, Pope JG, Peterson JD, Dal Canto MC, Miller SD (1995). Inhibition of Thelier's virus-mediated demyelination by peripheral immune tolerance induction. J Immunol 155: 947–957.

Koller B, Marrack P, Kappler J, Smithies O (1990). Normal development of mice deficient in β2-microglobulin, MHC class I proteins and CD8+ T cells. Science 248: 1227–1320.

Kurtzke JF (1993). Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev 6: 382–427.

Larsson-Sciard EL, Dethlefs S, Brahic M (1997). In vivo administration of interleukin-2 protects susceptible mice from Thelier’s virus persistence. J Virol 71: 797–799.

Lavi E, Das Sarma J, Weiss SR (1999). Cellular reservoirs for coronavirus infection of the brain in β2-microglobulin knockout mice. Pathobiology 67: 75–83.

Li L, Sad S, Kagi D, Mosmann TR (1997). CD8 Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions. J Immunol 158: 4152–4161.

Lin X, Thiemann NR, Pease LR, Rodriguez M (1995). VP1 and VP2 capsid proteins of Thelier’s virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Virology 214: 91–99.

Lindsley MD, Thiemann R, Rodriguez M (1991). Cytotoxic T cells isolated from the central nervous systems of mice infected with Thelier’s virus. J Virol 65: 6612–6620.

Lipton HL, Dal Canto MC (1979). Susceptibility of inbred mice to chronic central nervous system infection by Thelier’s murine encephalomyelitis virus. Infect Immun 26: 369–374.

Lipton HL, Gonzalez-Scarano F (1978). Central nervous system immunity in mice infected with Thelier’s virus. I. Local neutralizing antibody response. J Infect Dis 137: 145–151.

Lipton HL, Kratochvil J, Sethi P, Dal Canto MC (1984). Thelier’s virus antigen detected in mouse spinal cord 2½ years after infection. Neurology 34: 1117–1119.
Matloubian M, Concepcion RJ, Ahmed R (1994). CD4$^+$ T cells are required to sustain CD8$^+$ cytotoxic T-cell responses during chronic viral infection. *J Virol* **68**: 8056–8063.

Miller SD, Karpus WJ (1994). The immunopathogenesis and regulation of T-cell mediated demyelinating diseases. *Immunol Today* **15**: 356–361.

Miller SD, Vanderlugt CL, Begolka WS, Pao W, Yauch RL, Neville KL, Katz-Levy Y, Carriozoa A, Kim BS (1997). Persistent infection with Theiler's virus leads to CNS autoimmunity via epitope spreading. *Nat Med* **3**: 1133–1136.

Murray PD, Pavelko KD, Leibowitz J, Lin X, Rodriguez M (1998). CD4$^+$ and CD8$^+$ T cells make discrete contributions to demyelination and neurologic disease in a viral model of multiple sclerosis. *J Virol* **72**: 7320–7329.

Nicholson SM, Dal Canto MC, Miller SD, Melvold RW (1996). Adoptively transferred CD8$^+$ lymphocytes provide protection against TMEV-induced demyelinating disease in BALB/c mice. *J Immunol* **156**: 1276–1283.

Njenga MK, Pavelko KD, Baisch J, Lin X, David C, Leibowitz J, Rodriguez M (1996). Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice. *J Virol* **70**: 1729–1737.

Ohara Y, Konno H, Iwasaki Y, Yamamoto T, Terunuma H, Suzuki H (1990). Cytotropism of Theiler's murine encephalomyelitis viruses in oligodendrocyte-enriched cultures. *Arch Virol* **114**: 293–298.

Pena Rossi C, McAllister A, Fiette L, Brahic M (1991). Theiler's virus infection induces a specific cytotoxic T lymphocyte response. *Cell Immunol* **138**: 341–348.

Pena-Rossi C, McAllister A, Tanguy M, Kagi D, Brahic M (1998). Theiler's virus infection of perforin-deficient mice. *J Virol* **72**: 4515–4519.

Peterson JD, Karpus WJ, Clatch RJ, Miller SD (1993). Split tolerance of Th1 and Th2 cells in tolerance to Theiler's murine encephalomyelitis virus. *Eur J Immunol* **23**: 46–55.

Pope JG, Karpus WJ, Vanderlugt CL, Miller SD (1996). Flow cytometric and functional analyses of CNS-infiltrating cells in SJL/J mice with Theiler's virus-induced demyelinating disease: Evidence for a CD4$^+$ T cell-mediated pathology. *J Immunol* **156**: 4050–4058.

Pullen LC, Miller SD, Dal Canto MC, Kim BS (1993). Class I-deficient resistant mice intracerebrally inoculated with Theiler's virus show an increased T cell response to viral antigens and susceptibility to demyelination. *Eur J Immunol* **23**: 2287–2293.

Rivera-Quinones C, McGavern D, Schmelzer JD, Hunter SF, Low PA, Rodriguez M (1998). Absence of neurological deficits following extensive demyelination in a class I-deficient murine model of multiple sclerosis. *Nat Med* **4**: 187–193.

Rodriguez M, David CS (1985). Demyelination induced by Theiler's virus: Influence of the H-2 haplotype. *J Immunol* **135**: 2145–2148.

Rodriguez M, Dunkel AJ, Thiemann RL, Leibowitz J, Zijlstra M, Jaenisch R (1993). Abrogation of resistance to Theiler's virus-induced demyelination in H-2$^b$ mice deficient in $\beta_2$-microglobulin. *J Immunol* **151**: 266–276.

Rodriguez M, Lafuse WP, Leibowitz J, David CS (1986a). Partial suppression of Theiler's virus-induced demyelination in vivo by administration of monoclonal antibodies to immune-response gene products (Ia antigens). *Neurology* **36**: 964–970.

Rodriguez M, Leibowitz J, David CS (1986b). Susceptibility to Theiler's virus-induced demyelination. Mapping of the gene within the H-2D region. *J Exp Med* **163**: 620–631.

Rodriguez M, Leibowitz JL, Lampert PW (1983). Persistent infection of oligodendrocytes in Theiler's virus-induced encephalomyelitis. *Ann Neurol* **13**: 426–433.

Rodriguez M, Siegel LM, Hovanec-Burns D, Bologna L, Graves MC (1988). Theiler's virus-associated antigens on the surfaces of cultured glial cells. *Virology* **166**: 463–474.

Rodriguez M, Sriram S (1988). Successful therapy of Theiler's virus-induced demyelination (DA Strain) with monoclonal anti-I-2 antibody. *J Immunol* **140**: 2950–2955.

Sad S, Marcotte R, Mosmann TR (1995). Cytokine-induced differentiation of precursor mouse CD8$^+$ T cells into cytotoxic CD8$^+$ T cells secreting Th1 or Th2 cytokines. *Immunity* **2**: 271–279.

Sad S, Mosmann TR (1995). Interleukin (IL) 4, in the absence of antigen stimulation, induces an anergy-like state in differentiated CD8$^+$ T cells: Loss of IL-2 synthesis and autonomous proliferation but retention of cytotoxicity and synthesis of other cytokines. *J Exp Med* **182**: 1505–1515.

Seder RA, Le Gros G (1995). The functional role of CD8$^+$ T helper type 2 cells (comment). *J Exp Med* **181**: 5–7.

Waksman BH (1995). Multiple sclerosis: More genes versus environment. *Nature* **377**: 105–106.

Welsh CJ, Tonks P, Nash AA, Blakemore WF (1987). The effect of L3T4$^+$ T cell depletion on the pathogenesis of Theiler's murine encephalomyelitis virus infection in CBA mice. *J Gen Virol* **68**: 1659–1667.

Yauch RL, Palma JP, Yahikozawa H, Koh CS, Kim BS (1998). Role of individual T-cell epitopes of Theiler's virus in the pathogenesis of demyelination correlates with the ability to induce a Th1 response. *J Virol* **72**: 6169–6174.

Zijlstra M, Bix M, Simister NE, Loring JM, Rault DH, Jaenisch R (1990). Beta 2-microglobulin deficient mice lack CD4$^+$ and CD8$^+$ cytolytic T cells. *Nature* **344**: 742–746.